Corporate PresentationDownload July 2025 Presentation Select HighlightsJune 2, 2025News: STAT6 DC NominationView Press Release »May 18, 2025ATS Conference: STAT6 DataAccess Poster »May 8, 2025SID Conference: BTK DataAccess Poster » Latest Press ReleasesNovember 3, 2025Recludix Pharma to Present at Two Investor Conferences in NovemberRead More »September 11, 2025Recludix Pharma to Present at the Stifel 2025 Virtual Immunology and Inflammation ForumRead More »July 14, 2025Recludix Pharma Announces Strengthening of Leadership Team, Including Promotion of Dr. Brian Hodous to Chief Scientific OfficerRead More »June 2, 2025Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with SanofiRead More » More Press Releases Events and PresentationsNovember 11 at 11:20 a.m. ETStifel 2025 Healthcare ConferenceRegister Here »November 10 at 1:30 p.m. ET Guggenheim Second Annual Healthcare Innovation ConferenceRegister Here »September 16, 2025 3pm ETStifel 2025 Virtual Immunology and Inflammation ForumAccess Webcast »June 30, 2025Recludix Platform has Unlocked Development of Oral, Reversible Small Molecule Inhibitors of SH2 DomainsView Poster » More Events and Presentations News Coverage HighlightsAugust 7, 2023BioCentury: Recludix: targeting STATs via their SH2 domainsRead More »July 20, 2023BioWorld: Recludix enters a potential $1.2B deal with SanofiRead More »July 20, 2023SCRIP: Sanofi Adds To Immunology Pipeline In Collaboration With Recludix Read More »July 20, 2023Fierce Biotech: Sanofi pays $125M to go after undruggable inflammatory target with Recludix’s preclinical programRead More »July 20, 2023Endpoints News: Following Dupixent’s rise, Sanofi heads downstream in immunology for $125M small molecule pact with RecludixRead More »
